Thermodynamic and kinetic design principles for protein aggregation inhibitors

Thomas C. T. Michaels, Anđela Šarić, Georg Meisl, Gabriella T. Heller, Samo Curk, Paolo Arosio, Sara Linse, Christopher M. Dobson, Michele Vendruscolo, Tuomas P. J. KnowlesbioRxiv 2020 · DOI

TL;DR

This paper introduces a comprehensive kinetic theory to understand how inhibitors work against protein aggregation, a key process in diseases like Alzheimer's. By developing a master equation and deriving analytical solutions, the authors provide a framework to predict inhibitor effectiveness based on binding kinetics and thermodynamics, offering a powerful new tool for designing better drugs.

What Problem Does This Paper Address?

Protein aggregation is a complex process implicated in many neurodegenerative diseases, including Alzheimer's and Parkinson's. The challenge in developing effective inhibitors lies in the fact that protein aggregation involves a dynamic interplay of various species – monomers, oligomers, and fibrils – which can act as reactants, products, and even catalysts. This complexity makes it difficult to pinpoint which species an inhibitor should target and how its binding properties (thermodynamics and kinetics) translate into actual inhibition. Traditional approaches often focus on broad goals like delaying aggregation, but a deeper mechanistic understanding is needed to design inhibitors that are truly potent and specific.

Methods

The authors developed a kinetic theory of protein aggregation inhibition based on a master equation. This equation describes the time evolution of different species involved in aggregation (monomers, fibrils) and how they are affected by an inhibitor. They derived explicit integrated rate laws for the aggregation process in the presence of inhibitors. A key innovation is the ability to interpret the kinetics of inhibited aggregation in terms of effective rate parameters that directly incorporate the binding kinetics (association and dissociation rates) and thermodynamics (binding affinity) of the inhibitor. This allows for a quantitative link between inhibitor properties and their impact on aggregation. They also used numerical simulations to validate their analytical solutions.

Datasets

Not discussed in the paper. The paper focuses on developing a theoretical framework and validating it with existing experimental data (e.g., for Aβ42 aggregation).

Key Insights and Ideas

  • Unified Framework: The paper provides a single, unified theoretical framework to understand how inhibitors affect protein aggregation, regardless of whether they target monomers, fibril ends, or fibril surfaces.
  • Preservation of Aggregation Structure: A crucial finding is that inhibitors, under certain assumptions, preserve the fundamental structure of the aggregation reaction network. This means the overall sigmoidal shape of aggregation curves remains, but is modulated by effective rate parameters.
  • Inhibition Regimes: The theory identifies distinct inhibition regimes (inactive, non-equilibrium, and equilibrium) based on the interplay between the inhibitor's binding rate and the characteristic timescale of aggregation. This is critical for understanding when an inhibitor will be effective.
  • Thermodynamics and Kinetics are Key: The effectiveness of an inhibitor is not solely determined by its binding affinity (thermodynamics) but also by its binding kinetics (how fast it binds and unbinds). This offers new design principles beyond just maximizing binding strength.
  • Universal Timescale: The theory introduces a universal timescale (related to $\kappa$) that acts as a ruler for comparing inhibitor binding rates to the aggregation process.

Key Results

  • The derived integrated rate law for inhibited aggregation has the same functional form as the uninhibited case, but with effective rate parameters ($\lambda_{eff}$ and $\kappa_{eff}$) that depend on inhibitor binding.
  • The paper demonstrates that equilibrium inhibition (where inhibitor binding is fast compared to aggregation) leads to the maximum possible extent of inhibition for a given binding affinity.
  • Experimental data for Aβ42 aggregation inhibition by Brichos (a chaperone binding fibril surfaces) and 10074-G5 (a small molecule binding monomers) were well-reproduced by the theoretical model, validating its predictive power.
  • The analysis of Brichos showed it operates in a non-equilibrium inhibition regime, binding fibril surfaces relatively slowly compared to aggregation.
  • The study suggests that for monomer-binding inhibitors, faster on-rates (kon) are crucial for effective inhibition.

Limitations and Future Work

  • Assumptions: The model relies on certain assumptions, such as independent binding events and that bound species are unable to participate in aggregation. The authors note that real-world scenarios can be more complex, involving heterogeneous populations of aggregating species.
  • Generalizability: While the principles are generally applicable to linear self-assembly processes, further work is needed to extend the theory to inhibitors that bind multiple species simultaneously or to more complex aggregation pathways.
  • Experimental Validation: While the paper validates its theory with existing experimental data, future work could involve designing and testing new inhibitors based on the principles derived here.
  • Materials Science Applications: The authors suggest that these principles could be applied beyond protein aggregation to other self-assembly processes, such as in materials science, for controlling aggregate size and properties.

Summary updated

Abstract

Abstract Understanding the mechanism of action of compounds capable of inhibiting protein aggregation is critical to the development of potential ther-apeutics against protein misfolding diseases. A fundamental challenge for progress is the range of possible target species and the disparate timescales involved, since the aggregating proteins are simultaneously the reactants, products, intermediates and catalysts of the reaction. It is a complex problem, therefore, to choose the states of the aggregating proteins that should be bound by the compounds to achieve the most potent inhibition. We present here a comprehensive kinetic theory of protein aggregation inhibition which reveals the fundamental thermodynamic and kinetic signatures characterising effective inhibitors by identifying quantitative relationships between the aggregation and binding rate constants. These results provide general physical laws to guide the design and optimisation of protein aggregation inhibitors.
BibTeX
@misc{michaels2020thermodynamic,
  author = {Thomas C. T. Michaels and Anđela Šarić and Georg Meisl and Gabriella T. Heller and Samo Curk and Paolo Arosio and Sara Linse and Christopher M. Dobson and Michele Vendruscolo and Tuomas P. J. Knowles},
  title = {{Thermodynamic and kinetic design principles for protein aggregation inhibitors}},
  year = {2020},
  doi = {10.1101/2020.02.22.960716},
  howpublished = {bioRxiv},
}

Loading related content...

Figure